Madison Small Cap Fund, managed by Madison Funds, released its Q1 2026 investor letter. A copy of the letter is available to download here. The Madison Small Cap Fund (class I) increased by 0.10% in ...
The last time I spoke about Achieve Life Sciences (ACHV) it was with a Seeking Alpha article entitled "Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation." ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The FDA’s new practice of releasing redacted complete response letters (CRLs) in the name of “radical transparency” is ruffling some feathers in the drug industry, as illustrated through a new ...
FDA issued a second CRL for RP1+nivolumab, concluding the evidentiary package did not adequately support approval despite prior agency engagements suggestive of an accelerated-approval pathway. RP1 is ...
Section 22 of the Cultural, Religious and Linguistic (CRL) Rights Commission Act empowers the commission to investigate problems within religious communities, foster ethical conduct and address ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Wilmington company is ...
I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...
FDA rejected accelerated approval because Phase II biomarker reductions (whole-blood metal-free protoporphyrin IX) were not shown to correlate with sunlight exposure–based clinical benefit in the ...
Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new activist investor-led ...
Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results